Telmisartan to reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy: the TAILoR dose-ranging Phase II RCT. (2019)

First Author: Pushpakom S

Attributed to: TAILoR (TelmisArtan and InsuLin Resistance in HIV): A Dose-Ranging Phase II Randomised Open-Labelled Trial of Telmisartan as a Strategy for the Reduction of Insulin Resistance in HIV-Positive Individuals on Combination Antiretroviral Therapy (cART) funded by MRC

No abstract provided

Type: Journal Article/Review

Volume: 6

Parent Publication: NIHR Journals Library

Issue: 6